Market Research Logo

Atopic Dermatitis - Pipeline Review, H2 2016

Atopic Dermatitis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Atopic Dermatitis - Pipeline Review, H2 2016’, provides an overview of the Atopic Dermatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atopic Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis
  • The report reviews pipeline therapeutics for Atopic Dermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Atopic Dermatitis therapeutics and enlists all their major and minor projects
  • The report assesses Atopic Dermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Atopic Dermatitis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Atopic Dermatitis Overview
Therapeutics Development
Pipeline Products for Atopic Dermatitis - Overview
Pipeline Products for Atopic Dermatitis - Comparative Analysis
Atopic Dermatitis - Therapeutics under Development by Companies
Atopic Dermatitis - Therapeutics under Investigation by Universities/Institutes
Atopic Dermatitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Atopic Dermatitis - Products under Development by Companies
Atopic Dermatitis - Products under Investigation by Universities/Institutes
Atopic Dermatitis - Companies Involved in Therapeutics Development
AbbVie Inc
Accolade Pharmaceuticals, LLC
AlbireoPharma
Almirall, S.A.
Amgen Inc.
Amorepacific Corporation
Anacor Pharmaceuticals, Inc.
AnaMar AB
AnaptysBio, Inc.
AnGes MG, Inc.
arGEN-X BV
Avexxin AS
Blueberry Therapeutics Ltd
Brickell Biotech, Inc.
Celgene Corporation
Cell Medica Limited
Cellceutix Corporation
ChemoCentryx, Inc.
ChironWells GmbH
Chugai Pharmaceutical Co., Ltd.
Creabilis SA
Curapel Limited
Dermala Inc
Dr. August Wolff GmbH & Co. KG Arzneimittle
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Foamix Pharmaceuticals Ltd.
Fountain Biopharma Inc.
Galapagos NV
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
Grupo Ferrer Internacional, S.A.
Han Wha Pharma Co., Ltd.
HanAll Biopharma Co., Ltd.
Heptares Therapeutics Limited
Herantis Pharma Plc
iCo Therapeutics Inc.
Immune Pharmaceuticals Inc.
Inflamalps SA
Japan Tobacco Inc.
Johnson & Johnson
Kang Stem Biotech Co., Ltd.
KPI Therapeutics, Inc.
LegoChem Biosciences, Inc
LEO Pharma A/S
Madam Therapeutics B.V.
MedImmune, LLC
NeoPharm Co., Ltd.
Nippon Shinyaku Co., Ltd.
Novan, Inc.
Novartis AG
Orbis Biosciences Inc
Otsuka Holdings Co., Ltd.
Oxagen Limited
Pfizer Inc.
Pharis Biotec GmbH
Pharmedartis GmbH
Provectus Biopharmaceuticals, Inc.
PuriCore Plc
Quorum Innovations LLC
Regeneron Pharmaceuticals Inc
Signum Dermalogix, Inc
Spherium Biomed S.L.
sterna biologicals Gmbh & Co KG
Sucampo Pharmaceuticals, Inc.
Sun Pharma Advanced Research Company Ltd.
SWITCH Biotech LLC
Takeda Pharmaceutical Company Limited
Thesan Pharmaceuticals, Inc.
Tioga Pharmaceuticals, Inc.
Torrent Pharmaceuticals Limited
Valeant Pharmaceuticals International, Inc.
Vicore Pharma AB
Vitae Pharmaceuticals, Inc.
VivaCell Biotechnology Espana S.L.
Xencor, Inc.
Ziarco Pharma Ltd
Atopic Dermatitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-3914 - Drug Profile
A-5425 - Drug Profile
AKP-11 - Drug Profile
Allergen for House Dust Mite Induced Atopic Dermatitis - Drug Profile
ALX-101 - Drug Profile
AM-1030 - Drug Profile
AMG-0101 - Drug Profile
Anatabine - Drug Profile
ANB-020 - Drug Profile
apremilast - Drug Profile
Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile
ARGX-112 - Drug Profile
ARN-077 - Drug Profile
asimadoline - Drug Profile
AVX-001 - Drug Profile
B-244 - Drug Profile
baricitinib - Drug Profile
BB-2702 - Drug Profile
BBI-2000 - Drug Profile
BBI-5000 - Drug Profile
bertilimumab - Drug Profile
betamethasone valerate - Drug Profile
Biologic for Atopic Dermatitis and Eczema - Drug Profile
brilacidin tetrahydrochloride - Drug Profile
BTX-1204 - Drug Profile
C-21 - Drug Profile
CBP-174 - Drug Profile
CBP-201 - Drug Profile
CCX-6239 - Drug Profile
CDE-001 - Drug Profile
Cis-Urocanic Acid - Drug Profile
cobamamide - Drug Profile
crisaborole - Drug Profile
CT-101 - Drug Profile
CT-103 - Drug Profile
CT-327 - Drug Profile
CT-340 - Drug Profile
cyclosporine - Drug Profile
dalazatide - Drug Profile
DMT-210 - Drug Profile
Drug for Atopic Dermatitis - Drug Profile
dupilumab - Drug Profile
FB-825 - Drug Profile
fevipiprant - Drug Profile
FIB-116 - Drug Profile
Furestem-AD - Drug Profile
GBR-830 - Drug Profile
GLPG-2534 - Drug Profile
GSK-3772847A - Drug Profile
Histimex - Drug Profile
HS-378 - Drug Profile
IDP-124 - Drug Profile
JTE-052 - Drug Profile
KPI-150 - Drug Profile
LCB-030110 - Drug Profile
lebrikizumab - Drug Profile
LEKTI-6 - Drug Profile
LEO-32731 - Drug Profile
LEO-39652 - Drug Profile
MEDI-9314 - Drug Profile
mepolizumab - Drug Profile
MLR-1130 - Drug Profile
mometasone furoate - Drug Profile
Monoclonal Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation - Drug Profile
Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis - Drug Profile
Monoclonal Antibody to Target Th22 cell/IL-22 pathway for Inflammatory Bowel Diseases, Atopic Dermatitis and Colorectal Cancer - Drug Profile
N-oleoylethanolamine - Drug Profile
nemolizumab - Drug Profile
NPH-12 - Drug Profile
NS-141 - Drug Profile
OC-000459 - Drug Profile
OC-2417 - Drug Profile
octenidine hydrochloride - Drug Profile
OLX-103 - Drug Profile
omiganan pentahydrochloride - Drug Profile
OPA-15406 - Drug Profile
P-10 - Drug Profile
P-148 - Drug Profile
PAC-14028 - Drug Profile
Peptide to Antagonize CX3CR1 for Atopic Dermatitis - Drug Profile
Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
PF-04965842 - Drug Profile
PH-10 - Drug Profile
PL-601 - Drug Profile
PMA-101R - Drug Profile
PMA-201 - Drug Profile
PMA-411R - Drug Profile
PR-022 - Drug Profile
prednisone - Drug Profile
PZ-235 - Drug Profile
Q-301 - Drug Profile
Qi-507 - Drug Profile
roflumilast - Drug Profile
RTU-1096 - Drug Profile
RVT-501 - Drug Profile
SB-011 - Drug Profile
SB-414 - Drug Profile
secukinumab - Drug Profile
SIG-1311 - Drug Profile
SIG-1322 - Drug Profile
Small Molecule for Atopic Dermatitis - Drug Profile
Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile
Small Molecules for Atopic Dermatitis - Drug Profile
Small Molecules for Atopic Dermatitis - Drug Profile
Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
SP-14019 - Drug Profile
SUN-0597 - Drug Profile
SWT-01113 - Drug Profile
SWT-05141 - Drug Profile
Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile
tacrolimus - Drug Profile
tezepelumab - Drug Profile
tralokinumab - Drug Profile
upadacitinib tartrate - Drug Profile
ustekinumab - Drug Profile
VTP-38543 - Drug Profile
WBI-1001 - Drug Profile
WOL-071007 - Drug Profile
XmAb-7195 - Drug Profile
YJC-10592 - Drug Profile
Zafi-1 - Drug Profile
ZPL-389 - Drug Profile
ZPL-521 - Drug Profile
Atopic Dermatitis - Dormant Projects
Atopic Dermatitis - Discontinued Products
Atopic Dermatitis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Atopic Dermatitis, H2 2016
Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Investigation by Universities/Institutes, H2 2016
Atopic Dermatitis - Pipeline by AbbVie Inc, H2 2016
Atopic Dermatitis - Pipeline by Accolade Pharmaceuticals, LLC, H2 2016
Atopic Dermatitis - Pipeline by AlbireoPharma, H2 2016
Atopic Dermatitis - Pipeline by Almirall, S.A., H2 2016
Atopic Dermatitis - Pipeline by Amgen Inc., H2 2016
Atopic Dermatitis - Pipeline by Amorepacific Corporation, H2 2016
Atopic Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016
Atopic Dermatitis - Pipeline by AnaMar AB, H2 2016
Atopic Dermatitis - Pipeline by AnaptysBio, Inc., H2 2016
Atopic Dermatitis - Pipeline by AnGes MG, Inc., H2 2016
Atopic Dermatitis - Pipeline by arGEN-X BV, H2 2016
Atopic Dermatitis - Pipeline by Avexxin AS, H2 2016
Atopic Dermatitis - Pipeline by Blueberry Therapeutics Ltd, H2 2016
Atopic Dermatitis - Pipeline by Brickell Biotech, Inc., H2 2016
Atopic Dermatitis - Pipeline by Celgene Corporation, H2 2016
Atopic Dermatitis - Pipeline by Cell Medica Limited, H2 2016
Atopic Dermatitis - Pipeline by Cellceutix Corporation, H2 2016
Atopic Dermatitis - Pipeline by ChemoCentryx, Inc., H2 2016
Atopic Dermatitis - Pipeline by ChironWells GmbH, H2 2016
Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016
Atopic Dermatitis - Pipeline by Creabilis SA, H2 2016
Atopic Dermatitis - Pipeline by Curapel Limited, H2 2016
Atopic Dermatitis - Pipeline by Dermala Inc, H2 2016
Atopic Dermatitis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H2 2016
Atopic Dermatitis - Pipeline by Eli Lilly and Company, H2 2016
Atopic Dermatitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Atopic Dermatitis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
Atopic Dermatitis - Pipeline by Fountain Biopharma Inc., H2 2016
Atopic Dermatitis - Pipeline by Galapagos NV, H2 2016
Atopic Dermatitis - Pipeline by GlaxoSmithKline Plc, H2 2016
Atopic Dermatitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
Atopic Dermatitis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016
Atopic Dermatitis - Pipeline by Han Wha Pharma Co., Ltd., H2 2016
Atopic Dermatitis - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
Atopic Dermatitis - Pipeline by Heptares Therapeutics Limited, H2 2016
Atopic Dermatitis - Pipeline by Herantis Pharma Plc, H2 2016
Atopic Dermatitis - Pipeline by iCo Therapeutics Inc., H2 2016
Atopic Dermatitis - Pipeline by Immune Pharmaceuticals Inc., H2 2016
Atopic Dermatitis - Pipeline by Inflamalps SA, H2 2016
Atopic Dermatitis - Pipeline by Japan Tobacco Inc., H2 2016
Atopic Dermatitis - Pipeline by Johnson & Johnson, H2 2016
Atopic Dermatitis - Pipeline by Kang Stem Biotech Co., Ltd., H2 2016
Atopic Dermatitis - Pipeline by KPI Therapeutics, Inc., H2 2016
Atopic Dermatitis - Pipeline by LegoChem Biosciences, Inc, H2 2016
Atopic Dermatitis - Pipeline by LEO Pharma A/S, H2 2016
Atopic Dermatitis - Pipeline by Madam Therapeutics B.V., H2 2016
Atopic Dermatitis - Pipeline by MedImmune, LLC, H2 2016
Atopic Dermatitis - Pipeline by NeoPharm Co., Ltd., H2 2016
Atopic Dermatitis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016
Atopic Dermatitis - Pipeline by Novan, Inc., H2 2016
Atopic Dermatitis - Pipeline by Novartis AG, H2 2016
Atopic Dermatitis - Pipeline by Orbis Biosciences Inc, H2 2016
Atopic Dermatitis - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
Atopic Dermatitis - Pipeline by Oxagen Limited, H2 2016
Atopic Dermatitis - Pipeline by Pfizer Inc., H2 2016
Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H2 2016
Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H2 2016
Atopic Dermatitis - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016
Atopic Dermatitis - Pipeline by PuriCore Plc, H2 2016
Atopic Dermatitis - Pipeline by Quorum Innovations LLC, H2 2016
Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Atopic Dermatitis - Pipeline by Signum Dermalogix, Inc, H2 2016
Atopic Dermatitis - Pipeline by Spherium Biomed S.L., H2 2016
Atopic Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2016
Atopic Dermatitis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
Atopic Dermatitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
Atopic Dermatitis - Pipeline by SWITCH Biotech LLC, H2 2016
Atopic Dermatitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals, Inc., H2 2016
Atopic Dermatitis - Pipeline by Tioga Pharmaceuticals, Inc., H2 2016
Atopic Dermatitis - Pipeline by Torrent Pharmaceuticals Limited, H2 2016
Atopic Dermatitis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
Atopic Dermatitis - Pipeline by Vicore Pharma AB, H2 2016
Atopic Dermatitis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016
Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana S.L., H2 2016
Atopic Dermatitis - Pipeline by Xencor, Inc., H2 2016
Atopic Dermatitis - Pipeline by Ziarco Pharma Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Atopic Dermatitis - Dormant Projects, H2 2016
Atopic Dermatitis - Dormant Projects (Contd..1), H2 2016
Atopic Dermatitis - Dormant Projects (Contd..2), H2 2016
Atopic Dermatitis - Dormant Projects (Contd..3), H2 2016
Atopic Dermatitis - Dormant Projects (Contd..4), H2 2016
Atopic Dermatitis - Dormant Projects (Contd..5), H2 2016
Atopic Dermatitis - Dormant Projects (Contd..6), H2 2016
Atopic Dermatitis - Dormant Projects (Contd..7), H2 2016
Atopic Dermatitis - Dormant Projects (Contd..8), H2 2016
Atopic Dermatitis - Dormant Projects (Contd..9), H2 2016
Atopic Dermatitis - Discontinued Products, H2 2016
Atopic Dermatitis - Discontinued Products (Contd..1), H2 2016
List of Figures
Number of Products under Development for Atopic Dermatitis, H2 2016
Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report